XEL
71
18
VRSK
40
11
AIG
38
2
COF
30
-7
HON
55
3
TROW
27
-5
ECL
59
2
ALL
48
5
MTCH
32
-2
IR
63
2
RCL
57
3
SCHW
33
2
AMAT
50
2
DO
61
4
ADP
69
7
MMC
60
5
DTE
42
4
AXP
55
5
MPC
76
3
WRK
30
2
XEL
71
18
VRSK
40
11
AIG
38
2
COF
30
-7
HON
55
3
TROW
27
-5
ECL
59
2
ALL
48
5
MTCH
32
-2
IR
63
2
RCL
57
3
SCHW
33
2
AMAT
50
2
DO
61
4
ADP
69
7
MMC
60
5
DTE
42
4
AXP
55
5
MPC
76
3
WRK
30
2
Financhill
Back

Protagonist Therapeutics Quote, Financials, Valuation and Earnings

20-cent Gold Stock Has Backing of Major Gold Producers

The time to get in is now BEFORE next drill results are released.
Sell
41

PTGX
Protagonist Therapeutics

Last Price:
22.44
Seasonality Move:
22.79%

7 Day Trial

ALL ACCESS PASS

$ 7

Here's Your Own Billion-Dollar Trading Edge (Just $0.76 a Week)

And you can click here to get his three top picks to get started right now

Protagonist Therapeutics Price Quote

$22.44
+0.10 (+0.45%)
(Updated: March 30, 2023 at 11:50 PM ET)

Protagonist Therapeutics Key Stats

Sell
41
Protagonist Therapeutics (PTGX) is a Sell
Day range:
$20.85 - $22.38
52-week range:
$6.91 - $25.76
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
24.09
P/B ratio:
5.31%
Volume:
731.8K
Avg. volume:
2.2M
1-year change:
-11%
Market cap:
$1.1B
Revenue:
$26.6M
EPS:
$-2.6

How Much Does Protagonist Therapeutics Make?

Data Unavailable

Is Protagonist Therapeutics Growing As A Company?

Data Unavailable

Protagonist Therapeutics Stock Price Performance

What Is Protagonist Therapeutics 52-Week High & Low?

Protagonist Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Protagonist Therapeutics?

Is Protagonist Therapeutics Cash Flow Positive?

  • What Is PTGX Cash Flow From Operations?
    Cash flow from operations (TTM) is -$108.1M
  • What Is Protagonist Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $18.8M
  • What Is Protagonist Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $91.5M

Protagonist Therapeutics Return On Invested Capital

Data Unavailable

Protagonist Therapeutics Earnings Date & Stock Price

Protagonist Therapeutics Competitors

Protagonist Therapeutics Dividend Yield

Data Unavailable

Protagonist Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -12.97%
Revenue: 0% -100%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 34.50
Upside from Last Price: 54.43%

Major Shareholders

  • How many PTGX shares are owned by institutional investors?
    66.2M PTGX shares are owned by institutional investors
  • How many PTGX shares are owned by insiders?
    1.1M PTGX shares are owned by insiders